Pure Global
NCT06359080

Transcranial Photobiomodulation for Reducing Autism Symptoms in Children - Open Label Study (TPBMASDOL)

Transcranial Photobiomodulation for Reducing Autism Symptoms in Children.
JelikaLite LLC·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Autism Spectrum Disorder
Drug/Device/Intervention
Cognilum TM: Light Treatment Condition
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
JelikaLite LLC
Location
Brooklyn,New York, United States of America
Timeline & enrollment
Phase
N/A
Start date
May 08, 2022
End date
Dec 11, 2022
Enrollment
22 participants
Primary outcome

Change in Autism Symptoms

Summary

The hypothesis of the study is that photobiomodulation reduces symptoms of autism.
 Participants will be children between the ages of 2 and 7, who have been diagnosed with
 moderate to severe autism. Transcranial photobiomodulation will be administered to the
 children in the experimental condition twice a week for 10 weeks. Results will be measured
 through parental interviews, standardized CARS2 (Childhood Autism Rating Scales, 2nd Edition)
 and data collected from EEG.

ICD-10 classifications
Childhood autismAtypical autismAsperger syndromeNeurotic disorder, unspecifiedMental and behavioural disorders
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06359080
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06359080 through Pure Global AI's free database. This phase not specified trial is sponsored by JelikaLite LLC and is currently Completed. The study focuses on Autism Spectrum Disorder. Target enrollment is 22 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.